Patents by Inventor Ravi V. J. Chari

Ravi V. J. Chari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10238751
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VI). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: March 26, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Michael Louis Miller, Manami Shizuka
  • Patent number: 10233257
    Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: March 19, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
  • Publication number: 20190070305
    Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.
    Type: Application
    Filed: July 9, 2018
    Publication date: March 7, 2019
    Inventors: Ravi V.J. Chari, Michael Louis Miller
  • Patent number: 10208127
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: February 19, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V. J. Chari
  • Publication number: 20190038762
    Abstract: This invention relates to antibody-drug conjugates capable of delivering cytotoxic compounds to cancers expressing the guanylyl cyclase C (GCC) transmembrane cell surface receptor.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., IMMUNOGEN, INC.
    Inventors: Ole Petter VEIBY, Ravi V. J. CHARI, John M. LAMBERT, Katharine C. LAI, Robert W. HERBST, Scott A. HILDERBRAND
  • Patent number: 10179818
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: January 15, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V. J. Chari
  • Publication number: 20180355055
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: May 8, 2018
    Publication date: December 13, 2018
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
  • Publication number: 20180291100
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Application
    Filed: March 5, 2018
    Publication date: October 11, 2018
    Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Patent number: 10046063
    Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: August 14, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Michael Louis Miller
  • Patent number: 9974867
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 22, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Michael Louis Miller, Manami Shizuka
  • Publication number: 20180079828
    Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.
    Type: Application
    Filed: September 1, 2017
    Publication date: March 22, 2018
    Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V.J. Chari
  • Publication number: 20180079823
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: August 14, 2017
    Publication date: March 22, 2018
    Applicant: IMMUNOGEN, INC.
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
  • Publication number: 20180043013
    Abstract: New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the ?-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.
    Type: Application
    Filed: June 19, 2017
    Publication date: February 15, 2018
    Inventors: Ravi V.J. Chari, Wayne C. Widdison
  • Publication number: 20180002440
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 4, 2018
    Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V.J. Chari
  • Patent number: 9840564
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: December 12, 2017
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V. J. Chari
  • Publication number: 20170340749
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Application
    Filed: March 31, 2017
    Publication date: November 30, 2017
    Inventors: Ravi V.J. Chari, Michael Louis Miller, Manami Shizuka
  • Publication number: 20170340748
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VI). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 30, 2017
    Inventors: Ravi V.J. Chari, Michael Louis Miller, Manami Shizuka
  • Publication number: 20170274091
    Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.
    Type: Application
    Filed: January 26, 2017
    Publication date: September 28, 2017
    Inventors: Ravi V.J. Chari, Michael Louis Miller
  • Patent number: 9771432
    Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: September 26, 2017
    Assignee: IMMUNOGEN, INC.
    Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
  • Publication number: 20170226220
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: January 23, 2017
    Publication date: August 10, 2017
    Inventors: Ravi V.J. CHARI, Walter A. BLATTLER